One Source at a Time
Click to learn more!
Scientific Reports, 2020
.Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Psilocybin is a classic psychedelic compound that may have efficacy for the treatment of mood and substance use disorders. Acute psilocybin effects include reduced negative mood, increased positive mood, and reduced amygdala response to negative affective stimuli.
Results: The number of significant resting-state functional connections across the brain increased from baseline to 1-week and 1-month post-psilocybin. These preliminary findings suggest that psilocybin may increase emotional and brain plasticity.
Gukasyan, Natalie & Nayak, Sandeep. 2020
Psychedelics, placebo effects, and set and setting: insights from common factors theory of psychotherapy
In this paper they examine four major contextual “common factors” shared by various healing traditions - 1) the therapeutic relationship, 2) the healing setting, 3) the rationale, conceptual scheme, or myth, and 4) the ritual. Then researchers explain how these factors show up in psychedelic-assisted treatment and how they may contribute to therapeutic effects.
Regardless of their true mechanism, psychedelics show obvious promise as healing agents and may serve as an important tool to help us understand how to harness the “active psychological ingredients” of psychotherapy, set and setting, and placebo effects.
Psychopharmacology (Berl), 2017
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy.
CONCLUSIONS: Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort.
Journal of Psychopharmacology, 2016
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients.
At 6-month follow-up, these changes were sustained, with about 80% of participants continuing to show clinically significant decreases in depressed mood and anxiety.
Journal of Psychopharmacology, 2014
Pilot study of the 5-HT2AR agonist Psilocybin in the treatment of tobacco addiction
This early study showed 80% of participants had achieved smoking abstinence at a 6 month follow-up. Each participant in the study on average had: 6 previous lifetime quit attempts, 19 cigarettes per day for 31 years intake. Read the abstract for yourself.
The American Journal of Drug and Alcohol Abuse, 2017
Long-term follow-up of Psilocybin facilitated smoking cessation
At 12-month follow-up, 10 participants (67%) were biologically confirmed as smoking abstinent, with 8 of these participants reporting continuous abstinence since their Target-Quit-Date